ADMA Biologics is a late stage biopharmaceutical company that develops specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. ADMA Biologics was founded in 2004 and is based in Ramsey, New Jersey.